Immune Therapeutics, Inc. (IMUN) Enters Binding Letter of Intent to Acquire Innovative CAR-T Cell Technology
Before the opening bell, Immune Therapeutics, Inc. (OTCQB: IMUN) announced its entry into a binding letter of intent to acquire Chinese Chimeric Super Antigen Receptor T cell (CAR-T) cocktail therapy, pending immuno-oncology patents, manufacturing technology and clinical data regarding the aforementioned therapies from Super-T Cell Cancer Company (STCC), a newly-formed corporation. The technology outlined in this letter of intent could play a key role in IMUN’s ongoing efforts to achieve commercial approval for its patented immunotherapies, as described by Christopher Pearce, the company’s chief operating officer, in this morning’s news release: “This CAR-T cell technology licensing further accelerates IMUN's growth…